Document Detail


Approved and future pharmacotherapy for multiple sclerosis.
MedLine Citation:
PMID:  12803676     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Pharmacotherapy for relapsing-remitting multiple sclerosis (MS) advanced with the demonstration that interferon beta and glatiramer acetate improve the clinical course of this disease. Mitoxantrone is the first drug approved by the Food and Drug Administration for treatment of secondary progressive MS. Despite this progress, the agents presently available are only partially effective, are difficult to administer, and may have significant side effects. Several orally administered immunomodulatory agents are presently being evaluated for treatment of MS. One class of drugs, HMG CoA inhibitors (statins), is safe and well-tolerated and could become another mainstay of MS therapy. REVIEW SUMMARY: This article reviews the clinical evidence for approved MS therapies and discusses their mechanisms of action. Furthermore, the clinical and laboratory data suggesting a potential role for statins in MS therapy are discussed. CONCLUSIONS: Although treatment with interferon beta, glatiramer acetate, and mitoxantrone, the approved therapies, provide important treatment options for patients with relapsing-remitting MS and secondary progressive MS, the potential benefits of other medications, including statins, should be explored in controlled clinical trials.
Authors:
Olaf Stüve; Bruce C Cree; Hans-Christian von Büdingen; Sawsan Yousef; James D Bowen; Claude P Genain; Stephen L Hauser; Lawrence Steinman; Scott S Zamvil
Related Documents :
19283456 - Accurate potentiometric determination of lipid membrane-water partition coefficients an...
6874686 - Effect of tunicamycin on 3-hydroxy-3-methylglutaryl coenzyme a reductase in c-6 glial c...
1592416 - Conformational studies on cimetidine and ranitidine by pcilo calculations and nmr spect...
9402446 - Cholesterol lowering after participation in the scandinavian simvastatin survival study...
2420036 - Effect of intratracheally administered anticancer drugs on lung hydroxyproline content.
18369736 - Patterns of drug use in the public sector primary health centers of bhopal district.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The neurologist     Volume:  8     ISSN:  1074-7931     ISO Abbreviation:  Neurologist     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2003-06-13     Completed Date:  2003-11-18     Revised Date:  2004-02-25    
Medline Journal Info:
Nlm Unique ID:  9503763     Medline TA:  Neurologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  290-301     Citation Subset:  -    
Affiliation:
Department of Neurology, University of California, San Francisco 94143-0114, USA. ostuve@itsa.ucsf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Causes and management of thunderclap headache: a comprehensive review.
Next Document:  A practical approach to the diagnosis and management of MELAS: case report and review.